1
|
Nemours S, Armesto M, Arestín M, Manini C, Giustetto D, Sperga M, Pivovarcikova K, Pérez-Montiel D, Hes O, Michal M, López JI, Lawrie CH. Non-coding RNA and gene expression analyses of papillary renal neoplasm with reverse polarity (PRNRP) reveal distinct pathological mechanisms from other renal neoplasms. Pathology 2024; 56:493-503. [PMID: 38413252 DOI: 10.1016/j.pathol.2023.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 10/25/2023] [Accepted: 11/14/2023] [Indexed: 02/29/2024]
Abstract
Papillary renal neoplasm with reversed polarity (PRNRP) is a recently described rare renal neoplasm. Traditionally, it was considered a variant of papillary renal cell carcinoma (PRCC). However, several studies reported significant differences between PRNRP and PRCC in terms of clinical, morphological, immunohistochemical and molecular features. Nonetheless, PRNRP remains a poorly understood entity. We used microarray analysis to elucidate the non-coding RNA (ncRNA) and gene expression profiles of 10 PRNRP cases and compared them with other renal neoplasms. Unsupervised cluster analysis showed that PRNRP had distinct expression profiles from either clear cell renal cell carcinoma (ccRCC) or PRCC cases at the level of ncRNA but were less distinct at the level of gene expression. An integrated omic approach determined miRNA:gene interactions that distinguished PRNRP from PRCC and we validated 10 differentially expressed miRNAs and six genes by quantitative RT-PCR. We found that levels of the miRNAs, miR-148a, miR-375 and miR-429, were up-regulated in PRNRP cases compared to ccRCC and PRCC. miRNA target genes, including KRAS and VEGFA oncogenes, and CXCL8, which regulates VEGFA, were also differentially expressed between renal neoplasms. Gene set enrichment analysis (GSEA) determined different activation of metabolic pathways between PRNRP and PRCC cases. Overall, this study is by far the largest molecular study of PRNRP cases and the first to investigate either ncRNA expression or their gene expression by microarray assays.
Collapse
MESH Headings
- Humans
- Kidney Neoplasms/genetics
- Kidney Neoplasms/pathology
- Kidney Neoplasms/metabolism
- Carcinoma, Renal Cell/genetics
- Carcinoma, Renal Cell/pathology
- Carcinoma, Renal Cell/metabolism
- Middle Aged
- Female
- Male
- Aged
- RNA, Untranslated/genetics
- Gene Expression Profiling
- MicroRNAs/genetics
- MicroRNAs/metabolism
- Gene Expression Regulation, Neoplastic
- Adult
- Carcinoma, Papillary/pathology
- Carcinoma, Papillary/genetics
- Carcinoma, Papillary/metabolism
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
Collapse
Affiliation(s)
- Stéphane Nemours
- Biogipuzkoa Health Research Institute, Oncology Area, Molecular Oncology Group, San Sebastian, Spain
| | - María Armesto
- Biogipuzkoa Health Research Institute, Oncology Area, Molecular Oncology Group, San Sebastian, Spain
| | - María Arestín
- Biogipuzkoa Health Research Institute, Oncology Area, Molecular Oncology Group, San Sebastian, Spain
| | - Claudia Manini
- Department of Pathology, San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy; Department of Sciences of Public Health and Pediatrics, University of Turin, Italy
| | - Doriana Giustetto
- Department of Pathology, Maria Victoria Hospital, ASL Città di Torino, Turin, Italy
| | - Maris Sperga
- Department of Pathology, Stradin's University, Riga, Latvia
| | - Kristyna Pivovarcikova
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
| | | | - Ondrej Hes
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
| | - Michal Michal
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Bioptical Laboratory Ltd, Pilsen, Czech Republic
| | - José I López
- Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain
| | - Charles H Lawrie
- Biogipuzkoa Health Research Institute, Oncology Area, Molecular Oncology Group, San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain; Sino-Swiss Institute of Advanced Technology (SSIAT), University of Shanghai, Shanghai, China; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
| |
Collapse
|
2
|
Hano H, Lawrie CH, Suarez B, Paredes Lario A, Elejoste Echeverría I, Gómez Mediavilla J, Crespo Cruz MI, Lopez E, Seifert A. Power of Light: Raman Spectroscopy and Machine Learning for the Detection of Lung Cancer. ACS Omega 2024; 9:14084-14091. [PMID: 38559992 PMCID: PMC10975667 DOI: 10.1021/acsomega.3c09537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 02/22/2024] [Accepted: 02/27/2024] [Indexed: 04/04/2024]
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide, emphasizing the urgent need for reliable and efficient diagnostic methods. Conventional approaches often involve invasive procedures and can be time-consuming and costly, thereby delaying the effective treatment. The current study explores the potential of Raman spectroscopy, as a promising noninvasive technique, by analyzing human blood plasma samples from lung cancer patients and healthy controls. In a benchmark study, 16 machine learning models were evaluated by employing four strategies: the combination of dimensionality reduction with classifiers; application of feature selection prior to classification; stand-alone classifiers; and a unified predictive model. The models showed different performances due to the inherent complexity of the data, achieving accuracies from 0.77 to 0.85 and areas under the curve for receiver operating characteristics from 0.85 to 0.94. Hybrid methods incorporating dimensionality reduction and feature selection algorithms present the highest figures of merit. Nevertheless, all machine learning models deliver creditable scores and demonstrate that Raman spectroscopy represents a powerful method for future in vitro diagnostics of lung cancer.
Collapse
Affiliation(s)
- Harun Hano
- CIC
nanoGUNE BRTA, 20018 San Sebastián, Spain
- Department
of Physics, University of the Basque Country
(UPV/EHU), 20018 San Sebastián, Spain
| | - Charles H. Lawrie
- IKERBASQUE—Basque
Foundation for Science, 48009 Bilbao, Spain
- Biogipuzkoa
Health Research Institute, 20014 San Sebastián, Spain
- Sino-Swiss
Institute of Advanced Technology (SSIAT), University of Shanghai, 201800 Shanghai, China
- Radcliffe
Department of Medicine, University of Oxford, OX3 9DU Oxford, U.K.
| | - Beatriz Suarez
- Faculty
of Nursing and Medicine, University of the
Basque Country (UPV/EHU), 20014 San Sebastián, Spain
- Biogipuzkoa
Health Research Institute, 20014 San Sebastián, Spain
| | - Alfredo Paredes Lario
- Servicio
de Oncología Médica, Hospital
Universitario Donostia, 20014 San Sebastián, Spain
| | | | | | | | - Eneko Lopez
- CIC
nanoGUNE BRTA, 20018 San Sebastián, Spain
- Department
of Physics, University of the Basque Country
(UPV/EHU), 20018 San Sebastián, Spain
| | - Andreas Seifert
- CIC
nanoGUNE BRTA, 20018 San Sebastián, Spain
- IKERBASQUE—Basque
Foundation for Science, 48009 Bilbao, Spain
| |
Collapse
|
3
|
Tivanello RG, Lawrie CH, Bragotto APA. The role of microRNAs in the toxic mechanisms of furan and 3-MCPD and links to cancer risk - a review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2023:1-12. [PMID: 37249261 DOI: 10.1080/19440049.2023.2216793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Contaminants formed during food processing are of increasing concern to public and food safety experts, as well as international risk assessment organizations. The emergence of 'omic' technologies (e.g. genomics and transcriptomics) have greatly increased the mechanistic knowledge of the toxicity associated with these compounds, and consequently have provided a better understanding of their potential adverse effects. Of note, microRNAs (miRNAs) have emerged as being of key importance during the development of cancer as well as being associated with food-processing contaminants. MiRNAs have been demonstrated to trigger toxic processes in hepatic and renal tissues due to exposure to toxic compounds such as furan and 3-monochloropropane-1,2-diol (3-MCPD), respectively. In this review, we consider the roles of miRNAs in the toxicity process and the challenges that lay ahead in order to translate this knowledge to the benefit of industrial food processing.
Collapse
Affiliation(s)
- Renan G Tivanello
- Faculty of Food Engineering, University of Campinas (UNICAMP), Campinas, Brazil
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastian, Spain
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, China
| | | |
Collapse
|
4
|
Granda-Díaz R, Manterola L, Hermida-Prado F, Rodríguez R, Santos L, García-de-la-Fuente V, Fernández MT, Corte-Torres MD, Rodrigo JP, Álvarez-Teijeiro S, Lawrie CH, Garcia-Pedrero JM. Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways. Biomed Pharmacother 2023; 161:114512. [PMID: 36931033 DOI: 10.1016/j.biopha.2023.114512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 03/07/2023] [Accepted: 03/09/2023] [Indexed: 03/18/2023] Open
Abstract
Treatment of head and neck squamous cell carcinomas (HNSCC), the sixth most frequent cancer worldwide, remains challenging. miRNA dysregulation is closely linked to tumorigenesis and tumor progression, thus emerging as suitable targets for cancer treatment. Transcriptomic analysis of TCGA HNSCC dataset revealed that miR-301a expression levels significantly increased in primary tumors, as compared to patient-matched normal tissue. This prompted us to investigate its pathobiological role and potential as new therapeutic target using different preclinical HNSCC models. miR-301a overexpression in HNSCC-derived cell lines led to enhanced proliferation and invasion, whereas miR-301 inhibition reduced these effects. In vivo validation was performed using an orthotopic mouse model. Results concordantly showed that the mitotic counts, the percentage of infiltration depth and Ki67 proliferative index were significantly augmented in the subgroup of mice harboring miR-301a-overexpressing tumors. Further mechanistic characterization revealed PI3K/PTEN/AKT and MEK/ERK pathways as central signaling nodes responsible for mediating the oncogenic activity of miR-301a observed in HNSCC cells. Notably, pharmacological disruption of PI3K and ERK signals with BYL-719 and PD98059, respectively, was effective to completely revert/abolish miR-301a-promoted tumor cell growth and invasion. Altogether, these findings demonstrate that miR-301a dysregulation plays an oncogenic role in HNSCC, thus emerging as a candidate therapeutic target for this disease. Importantly, available PI3K and ERK inhibitors emerge as promising anti-tumor agents to effectively target miR-301a-mediated signal circuit hampering growth-promoting and pro-invasive functions.
Collapse
Affiliation(s)
- Rocío Granda-Díaz
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Lorea Manterola
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián, Spain
| | - Francisco Hermida-Prado
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - René Rodríguez
- CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Sarcomas and Experimental Therapies, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain
| | - Laura Santos
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain
| | - Vanessa García-de-la-Fuente
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain
| | - María Teresa Fernández
- Histopathology Unit, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain
| | - M Daniela Corte-Torres
- Biobank of Principado de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Juan P Rodrigo
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Saúl Álvarez-Teijeiro
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
| | - Charles H Lawrie
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, China.
| | - Juana M Garcia-Pedrero
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), University of Oviedo, Oviedo, Spain; Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
5
|
Armesto M, Charconnet M, Marimón JM, Fernández Regueiro CL, Jia J, Yan T, Sorarrain A, Grzelczak M, Sanromán M, Vicente M, Klempa B, Zubiria J, Peng Y, Zhang L, Zhang J, Lawrie CH. Validation of Rapid and Economic Colorimetric Nanoparticle Assay for SARS-CoV-2 RNA Detection in Saliva and Nasopharyngeal Swabs. Biosensors (Basel) 2023; 13:275. [PMID: 36832041 PMCID: PMC9954569 DOI: 10.3390/bios13020275] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 02/08/2023] [Accepted: 02/13/2023] [Indexed: 06/16/2023]
Abstract
Even with the widespread uptake of vaccines, the SARS-CoV-2-induced COVID-19 pandemic continues to overwhelm many healthcare systems worldwide. Consequently, massive scale molecular diagnostic testing remains a key strategy to control the ongoing pandemic, and the need for instrument-free, economic and easy-to-use molecular diagnostic alternatives to PCR remains a goal of many healthcare providers, including WHO. We developed a test (Repvit) based on gold nanoparticles that can detect SARS-CoV-2 RNA directly from nasopharyngeal swab or saliva samples with a limit of detection (LOD) of 2.1 × 105 copies mL-1 by the naked eye (or 8 × 104 copies mL-1 by spectrophotometer) in less than 20 min, without the need for any instrumentation, and with a manufacturing price of <$1. We tested this technology on 1143 clinical samples from RNA extracted from nasopharyngeal swabs (n = 188), directly from saliva samples (n = 635; assayed by spectrophotometer) and nasopharyngeal swabs (n = 320) from multiple centers and obtained sensitivity values of 92.86%, 93.75% and 94.57% and specificities of 93.22%, 97.96% and 94.76%, respectively. To our knowledge, this is the first description of a colloidal nanoparticle assay that allows for rapid nucleic acid detection at clinically relevant sensitivity without the need for external instrumentation that could be used in resource-limited settings or for self-testing.
Collapse
Affiliation(s)
- María Armesto
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain
| | - Mathias Charconnet
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
| | - José M. Marimón
- Respiratory Infection and Antimicrobial Resistance Group, Biodonostia Research Institute, 20014 San Sebastián, Spain
| | | | - Jia Jia
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
- School of Life Sciences, Shanghai University, Shanghai 201907, China
| | - Tingdong Yan
- School of Life Sciences, Shanghai University, Shanghai 201907, China
| | - Ane Sorarrain
- Respiratory Infection and Antimicrobial Resistance Group, Biodonostia Research Institute, 20014 San Sebastián, Spain
| | - Marek Grzelczak
- Colloidal Systems Chemistry, Centro de Física de Materiales (CSIC-UPV/EHU), 20018 San Sebastián, Spain
- Donostia Institute of Physics Centre (DIPC), 20018 San Sebastián, Spain
| | - María Sanromán
- Colloidal Systems Chemistry, Centro de Física de Materiales (CSIC-UPV/EHU), 20018 San Sebastián, Spain
- Donostia Institute of Physics Centre (DIPC), 20018 San Sebastián, Spain
| | - Mónica Vicente
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain
| | - Boris Klempa
- Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Dúbravská Cesta 9, Bratislava 845 05, Slovakia
| | - Javier Zubiria
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
| | - Yuan Peng
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
| | - Lei Zhang
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
| | - Jianhua Zhang
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
- School of Microelectronics, Shanghai University, Shanghai 201907, China
| | - Charles H. Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201907, China
- IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
- Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
| |
Collapse
|
6
|
Lawrie CH. Progress in the blood-based diagnosis of oesophageal squamous cell carcinoma (ESCC) using microRNAs: Comment on Komatsu et al. (BJC (2011) 105, 104-111). Br J Cancer 2023; 128:446-447. [PMID: 36307646 PMCID: PMC9938217 DOI: 10.1038/s41416-022-02034-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 10/14/2022] [Accepted: 10/17/2022] [Indexed: 11/09/2022] Open
Affiliation(s)
- Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, 20014, San Sebastian, Spain.
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
- Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, China.
| |
Collapse
|
7
|
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest 2022; 132:165107. [PMID: 36169029 PMCID: PMC9525111 DOI: 10.1172/jci165107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Aldaz P, Martín-Martín N, Saenz-Antoñanzas A, Carrasco-Garcia E, Álvarez-Satta M, Elúa-Pinin A, Pollard SM, Lawrie CH, Moreno-Valladares M, Samprón N, Hench J, Lovell-Badge R, Carracedo A, Matheu A. High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML. Int J Mol Sci 2022; 23:ijms23094511. [PMID: 35562901 PMCID: PMC9104987 DOI: 10.3390/ijms23094511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 04/12/2022] [Accepted: 04/18/2022] [Indexed: 01/27/2023] Open
Abstract
Glioma stem cells (GSCs) are critical targets for glioma therapy. SOX9 is a transcription factor with critical roles during neurodevelopment, particularly within neural stem cells. Previous studies showed that high levels of SOX9 are associated with poor glioma patient survival. SOX9 knockdown impairs GSCs proliferation, confirming its potential as a target for glioma therapy. In this study, we characterized the function of SOX9 directly in patient-derived glioma stem cells. Notably, transcriptome analysis of GSCs with SOX9 knockdown revealed STAT3 and PML as downstream targets. Functional studies demonstrated that SOX9, STAT3, and PML form a regulatory loop that is key for GSC activity and self-renewal. Analysis of glioma clinical biopsies confirmed a positive correlation between SOX9/STAT3/PML and poor patient survival among the cases with the highest SOX9 expression levels. Importantly, direct STAT3 or PML inhibitors reduced the expression of SOX9, STAT3, and PML proteins, which significantly reduced GSCs tumorigenicity. In summary, our study reveals a novel role for SOX9 upstream of STAT3, as a GSC pathway regulator, and presents pharmacological inhibitors of the signaling cascade.
Collapse
Affiliation(s)
- Paula Aldaz
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
| | - Natalia Martín-Martín
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 48160 Derio, Spain; (N.M.-M.); (A.C.)
| | - Ander Saenz-Antoñanzas
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
| | - Estefania Carrasco-Garcia
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
- CIBER of Frailty and Healthy Aging (CIBERFES), Carlos III Institute, 28029 Madrid, Spain
| | - María Álvarez-Satta
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
| | | | - Steven M. Pollard
- Centre for Regenerative Medicine & Edinburgh Cancer Research UK Centre, Institute for Regeneration and Repair, Edinburgh EH16 4UU, UK;
| | - Charles H. Lawrie
- Group of Molecular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain;
- Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain
| | - Manuel Moreno-Valladares
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
- Donostia University Hospital, 20014 San Sebastian, Spain;
| | - Nicolás Samprón
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
- Donostia University Hospital, 20014 San Sebastian, Spain;
| | - Jürgen Hench
- Institute of Pathology, University Hospital Basel, 48009 Basel, Switzerland;
| | | | - Arkaitz Carracedo
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 48160 Derio, Spain; (N.M.-M.); (A.C.)
- Institute of Pathology, University Hospital Basel, 48009 Basel, Switzerland;
- Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- CIBER of Cancer (CIBERONC), Carlos III Institute, 28029 Madrid, Spain
| | - Ander Matheu
- Group of Cellular Oncology, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (P.A.); (A.S.-A.); (E.C.-G.); (M.Á.-S.); (M.M.-V.); (N.S.)
- CIBER of Frailty and Healthy Aging (CIBERFES), Carlos III Institute, 28029 Madrid, Spain
- Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain
- Correspondence: ; Tel.: +34-943006073
| |
Collapse
|
9
|
Manini C, López-Fernández E, Lawrie CH, Laruelle A, Angulo JC, López JI. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level. Curr Urol Rep 2022; 23:93-97. [PMID: 35416538 DOI: 10.1007/s11934-022-01095-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/07/2022] [Indexed: 12/20/2022]
Abstract
PURPOSE OF REVIEW Intratumor heterogeneity (ITH) is an inherent characteristic of most tumors and its detection remains a key task for pathologists. However, the clinical significance of the degree of development of this feature is still poorly understood. RECENT FINDINGS A series of 28 clear cell renal cell carcinomas (CCRCC) have been exhaustively analyzed with two different sampling protocols [multisite tumor sampling (MSTS) and total sampling] to evaluate to what point the level (low vs. high) of histological ITH detected in routine practice influences tumor behavior and patients' survival. All CCRCC (n = 14) pursuing an aggressive clinical course presented low levels of ITH. A significant worse survival was detected in CCRCC with low ITH (p < 0.001). The simple quantification of the level of ITH using extensive sampling protocol may be of help in predicting tumor evolution, since all CCRCC with aggressive behavior demonstrated low levels of histological ITH.
Collapse
Affiliation(s)
- Claudia Manini
- Department of Pathology, San Giovanni Bosco Hospital, 10154, Turin, Italy.,Department of Sciences of Public Health and Pediatrics, University of Turin, 10124, Turin, Italy
| | - Estíbaliz López-Fernández
- FISABIO Foundation, 46020, Valencia, Spain.,Department of Health Sciences, European University of Valencia, 46023, Valencia, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, 20014, San Sebastian, Gipuzkoa, Spain.,Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9BQ, UK.,Basque Foundation for Science, IKERBASQUE, 48011, Bilbao, Bizkaia, Spain
| | - Annick Laruelle
- Basque Foundation for Science, IKERBASQUE, 48011, Bilbao, Bizkaia, Spain.,Department of Economic Analysis, University of the Basque Country (UPV/EHU), 48015, Bilbao, Spain
| | - Javier C Angulo
- Clinical Department, Faculty of Medical Sciences, European University of Madrid, 28005, Madrid, Spain.,Department of Urology, University Hospital of Getafe, 28907, Getafe, Madrid, Spain
| | - José I López
- Department of Pathology, Cruces University Hospital, Plaza de Cruces S/N, 48903, Barakaldo, Bizkaia, Spain. .,Biomarkers in Cancer Group, Biocruces-Bizkaia Research Institute, 48903, Barakaldo, Spain.
| |
Collapse
|
10
|
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martin-Martin N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazon A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment. J Clin Invest 2022; 132:148667. [PMID: 35192545 PMCID: PMC8970678 DOI: 10.1172/jci148667] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 02/16/2022] [Indexed: 11/17/2022] Open
Abstract
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.
Collapse
Affiliation(s)
- Angela M Araujo
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Andrea Abaurrea
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Peio Azcoaga
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | | | - Sara Manzano
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Javier Rodriguez
- Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain
| | - Ricardo Rezola
- Department of Pathology, Gipuzkoa Cancer Unit, OSI Donostialdea - Onkologikoa Foundation, San Sebastian, Spain
| | - Leire Egia-Mendikute
- Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences, Derio, Spain
| | - Fátima Valdés-Mora
- Cancer Epigenetic Biology and Therapeutics Laboratory, Children's Cancer Institute, Sydney, Australia
| | - Juana M Flores
- Department of Animal Surgery and Medicine, Complutense University of Madrid, Madrid, Spain
| | - Liam Jenkins
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Laura Pulido
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | | | | | - Nicola Ferrari
- Tumour Microenvironment Laboratory, The Institute of Cancer Research, London, United Kingdom
| | - Cristina Viera
- Center for Cooperative Research in Biosciences, Derio, Spain
| | - Natalia Martin-Martin
- Department of Molecular Oncology, Center for Cooperative Research in Biosciences, Derio, Spain
| | - Alexandar Tzankov
- Institute of Medical Genetics and Pathology, University of Basel, Basel, Switzerland
| | | | - Isabel Alvarez-Lopez
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Ander Urruticoechea
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Paloma Bragado
- Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain
| | - Nicholas Coleman
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Asis Palazon
- Parque Tecnológico de Bizkaia, Center for Cooperative Research in Biosciences, Derio, Spain
| | - Arkaitz Carracedo
- Proteomics Unit, Center for Cooperative Research in Biosciences, Derio, Spain
| | - David Gallego-Ortega
- Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia
| | - Fernando Calvo
- Tumour Microenvironment Lab, The Institute of Cancer Research, London, United Kingdom
| | - Clare M Isacke
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Maria M Caffarel
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Charles H Lawrie
- Department of Oncology, Biodonostia Health Research Institute, San Sebastian, Spain
| |
Collapse
|
11
|
Carrasco-Garcia E, Lopez L, Moncho-Amor V, Carazo F, Aldaz P, Collado M, Bell D, Gaafar A, Karamitopoulou E, Tzankov A, Hidalgo M, Rubio Á, Serrano M, Lawrie CH, Lovell-Badge R, Matheu A. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers (Basel) 2022; 14:cancers14040916. [PMID: 35205666 PMCID: PMC8870732 DOI: 10.3390/cancers14040916] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/09/2022] [Accepted: 02/09/2022] [Indexed: 12/24/2022] Open
Abstract
Simple Summary Pancreatic cancers are lethal types of cancer. A majority of patients progress to an advanced and metastatic disease, which remains a major clinical problem. Therefore, it is crucial to identify critical regulators to help predict the disease progression and to develop more efficacious therapeutic approaches. In this work we found that an increased expression of the developmental factor SOX9 is associated with metastasis, a poor prognosis and resistance to therapy in pancreatic ductal adenocarcinoma patients and in cell cultures. We also found that this effect is at least in part due to the ability of SOX9 to regulate the activity of stem cell factors, such as BMI1, in addition to those involved in EMT and metastasis. Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers mainly due to spatial obstacles to complete resection, early metastasis and therapy resistance. The molecular events accompanying PDAC progression remain poorly understood. SOX9 is required for maintaining the pancreatic ductal identity and it is involved in the initiation of pancreatic cancer. In addition, SOX9 is a transcription factor linked to stem cell activity and is commonly overexpressed in solid cancers. It cooperates with Snail/Slug to induce epithelial-mesenchymal transition (EMT) during neural development and in diseases such as organ fibrosis or different types of cancer. Methods: We investigated the roles of SOX9 in pancreatic tumor cell plasticity, metastatic dissemination and chemoresistance using pancreatic cancer cell lines as well as mouse embryo fibroblasts. In addition, we characterized the clinical relevance of SOX9 in pancreatic cancer using human biopsies. Results: Gain- and loss-of-function of SOX9 in PDAC cells revealed that high levels of SOX9 increased migration and invasion, and promoted EMT and metastatic dissemination, whilst SOX9 silencing resulted in metastasis inhibition, along with a phenotypic reversion to epithelial features and loss of stemness potential. In both contexts, EMT factors were not altered. Moreover, high levels of SOX9 promoted resistance to gemcitabine. In contrast, overexpression of SOX9 was sufficient to promote metastatic potential in K-Ras transformed MEFs, triggering EMT associated with Snail/Slug activity. In clinical samples, SOX9 expression was analyzed in 198 PDAC cases by immunohistochemistry and in 53 patient derived xenografts (PDXs). SOX9 was overexpressed in primary adenocarcinomas and particularly in metastases. Notably, SOX9 expression correlated with high vimentin and low E-cadherin expression. Conclusions: Our results indicate that SOX9 facilitates PDAC progression and metastasis by triggering stemness and EMT.
Collapse
Affiliation(s)
- Estefania Carrasco-Garcia
- Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (L.L.); (V.M.-A.); (P.A.)
- CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), 28029 Madrid, Spain
- Correspondence: (E.C.-G.); (A.M.); Tel.: +34-943-006073 (E.C.-G. & A.M.); Fax: +34-943-006250 (E.C.-G. & A.M.)
| | - Lidia Lopez
- Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (L.L.); (V.M.-A.); (P.A.)
| | - Veronica Moncho-Amor
- Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (L.L.); (V.M.-A.); (P.A.)
- The Francis Crick Institute, London NW1 1AT, UK; (D.B.); (R.L.-B.)
| | - Fernando Carazo
- School of Engineering, University of Navarra, 20009 San Sebastian, Spain; (F.C.); (Á.R.)
| | - Paula Aldaz
- Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (L.L.); (V.M.-A.); (P.A.)
| | - Manuel Collado
- Health Research Institute of Santiago de Compostela (IDIS), Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), 15706 Santiago de Compostela, Spain;
| | - Donald Bell
- The Francis Crick Institute, London NW1 1AT, UK; (D.B.); (R.L.-B.)
| | - Ayman Gaafar
- Department of Pathology, Cruces University Hospital, 48903 Barakaldo, Spain;
| | | | - Alexandar Tzankov
- Institute of Pathology, University Hospital Basel, 4056 Basel, Switzerland;
| | - Manuel Hidalgo
- Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain;
- New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10065, USA
| | - Ángel Rubio
- School of Engineering, University of Navarra, 20009 San Sebastian, Spain; (F.C.); (Á.R.)
| | - Manuel Serrano
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain;
- Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
| | - Charles H. Lawrie
- Molecular Oncology Group, Biodonostia Institute, 20014 San Sebastian, Spain;
- IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
| | | | - Ander Matheu
- Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; (L.L.); (V.M.-A.); (P.A.)
- CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), 28029 Madrid, Spain
- IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
- Correspondence: (E.C.-G.); (A.M.); Tel.: +34-943-006073 (E.C.-G. & A.M.); Fax: +34-943-006250 (E.C.-G. & A.M.)
| |
Collapse
|
12
|
Abstract
CircRNAs are a subclass of lncRNAs that have been found to be abundantly present in a wide range of species, including humans. CircRNAs are generally produced by a noncanonical splicing event called backsplicing that is dependent on the canonical splicing machinery, giving rise to circRNAs classified into three main categories: exonic circRNA, circular intronic RNA, and exon-intron circular RNA. Notably, circRNAs possess functional importance and display their functions through different mechanisms of action including sponging miRNAs, or even being translated into functional proteins. In addition, circRNAs also have great potential as biomarkers, particularly in cancer, thanks to their high stability, tissue type and developmental stage specificity, and their presence in biological fluids, which make them promising candidates as noninvasive biomarkers. In this chapter, we describe the most commonly used techniques for the study of circRNAs as cancer biomarkers, including high-throughput techniques such as RNA-Seq and microarrays, and other methods to analyze the presence of specific circRNAs in patient samples.
Collapse
Affiliation(s)
- Carla Solé
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Gartze Mentxaka
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain. .,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. .,Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
| |
Collapse
|
13
|
Arnaiz E, Miar A, Bridges E, Prasad N, Hatch SB, Ebner D, Lawrie CH, Harris AL. Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs. BMC Cancer 2021; 21:896. [PMID: 34353313 PMCID: PMC8344147 DOI: 10.1186/s12885-021-08616-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 07/15/2021] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resistance is common, therefore new therapies are needed. METHODS We assessed the effect of the HIF2α antagonist PT2385 in several steps of tumour development and performed RNAseq to identify genes differentially expressed upon treatment. A drug screening was used to identify drugs with antiproliferative effects on VHL-mutated HIF2α-expressing cells and could increase effectiveness of PT2385. RESULTS PT2385 did not reduce cell proliferation or clonogenicity but, in contrast to the genetic silencing of HIF2α, it reduced in vitro cell invasion. Many HIF-inducible genes were down-regulated upon PT2385 treatment, whereas some genes involved in cell migration or extracellular matrix were up-regulated. HIF2α was associated with resistance to statins, addition to PT2385 did not increase the sensitivity. CONCLUSIONS this study shows key differences between inhibiting a target versus knockdown, which are potentially targetable.
Collapse
Affiliation(s)
- Esther Arnaiz
- Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
| | - Ana Miar
- Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK.
| | - Esther Bridges
- Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
| | - Naveen Prasad
- Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK
| | - Stephanie B Hatch
- Nuffield Department of Medicine, NDM Research Building, University of Oxford, Oxford, OX3 7DQ, UK
| | - Daniel Ebner
- Nuffield Department of Medicine, NDM Research Building, University of Oxford, Oxford, OX3 7DQ, UK
| | - Charles H Lawrie
- Department of Oncology, Molecular Oncology Group, Biodonostia Health Research Institute, Paseo Doctor Begiristain s/n, 20014, San-Sebastián, Spain
| | - Adrian L Harris
- Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
| |
Collapse
|
14
|
Feiner IVJ, Pulagam KR, Uribe KB, Passannante R, Simó C, Zamacola K, Gómez-Vallejo V, Herrero-Álvarez N, Cossío U, Baz Z, Caffarel MM, Lawrie CH, Vugts DJ, Rejc L, Llop J. Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. J Mater Chem B 2021; 9:410-420. [PMID: 33367431 DOI: 10.1039/d0tb01880e] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer treatment exploiting the neutron capture capacity and subsequent fission reaction of boron-10. The emergence of nanotechnology has encouraged the development of nanocarriers capable of accumulating boron atoms preferentially in tumour cells. However, a long circulation time, required for high tumour accumulation, is usually accompanied by accumulation of the nanosystem in organs such as the liver and the spleen, which may cause off-target side effects. This could be overcome by using small-sized boron carriers via a pre-targeting strategy. Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Enhanced tumour accumulation was achieved when using a pretargeting approach, which was accomplished by a highly selective biorthogonal reaction at the tumour site with trans-cyclooctene-functionalised Trastuzumab.
Collapse
Affiliation(s)
- Irene V J Feiner
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Krishna R Pulagam
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Kepa B Uribe
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Rossana Passannante
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Cristina Simó
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Kepa Zamacola
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Vanessa Gómez-Vallejo
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | | | - Unai Cossío
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Zuriñe Baz
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - María M Caffarel
- Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Charles H Lawrie
- Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain and Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Danielle J Vugts
- Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. Radiology & Nuclear Medicine, The Netherlands
| | - Luka Rejc
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. and University of Ljubljana, Faculty of Chemistry and Chemical Technology, Večna pot 113, 1000 Ljubljana, Slovenia
| | - Jordi Llop
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. and Centro de Investigación Biomédica en Red, Enfermedades Respiratorias - CIBERES, Madrid, Spain
| |
Collapse
|
15
|
Groult H, Carregal-Romero S, Castejón D, Azkargorta M, Miguel-Coello AB, Pulagam KR, Gómez-Vallejo V, Cousin R, Muñoz-Caffarel M, Lawrie CH, Llop J, Piot JM, Elortza F, Maugard T, Ruiz-Cabello J, Fruitier-Arnaudin I. Heparin length in the coating of extremely small iron oxide nanoparticles regulates in vivo theranostic applications. Nanoscale 2021; 13:842-861. [PMID: 33351869 DOI: 10.1039/d0nr06378a] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The positive contrast of extremely small iron oxide nanoparticles (ESIONP) in magnetic resonance imaging (MRI) rejuvenates this class of metal nanoparticles (NP).Yet, the current synthesis often lacks the possibility of adjusting the core size (while it is a key element for ESIONP-based MRI contrast behaviour), and also involved multiple complex steps before obtaining a ready-to-use probe for medical applications. In this study, we faced these challenges by applying heparin oligosaccharides (HO) of different lengths as coatings for the preparation of HEP-ESIONP with a one-pot microwave method. We demonstrated that the HO length could control the core size during the synthesis to achieve optimal positive MRI contrast, and that HEP-ESIONP were endowed directly with anticoagulant properties and/or a specific antitumor activity, according to the HO used. Relevantly, positron emission tomography (PET)-based in vivo biodistribution study conducted with 68Ga core-doped HEP-ESIONP analogues revealed significant changes in the probe behaviours, the shortening of HO promoting a shift from hepatic to renal clearance. The different conformations of HO coatings and a thorough in vitro characterisation of the probes' protein coronas provided insight into this crucial impact of HO length on opsonization-mediated immune response and elimination. Overall, we were able to identify a precise HO length to get an ESIONP probe showing prolonged vascular lifetime and moderate accumulation in a tumor xenograft, balanced with a low uptake by non-specific organs and favourable urinary clearance. This probe met all prerequisites for advanced theranostic medical applications with a dual MRI/PET hot spot capability and potential antitumor activity.
Collapse
Affiliation(s)
- Hugo Groult
- BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France.
| | - Susana Carregal-Romero
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - David Castejón
- Unidad de RMN - CAI Bioimagen Complutense, Universidad Complutense de Madrid, Spain
| | - Mikel Azkargorta
- Proteomics Platform CIC bioGUNE, Bizkaia Science and Technology, Derio, Spain
| | - Ana-Beatriz Miguel-Coello
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain.
| | - Krishna Reddy Pulagam
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain.
| | - Vanessa Gómez-Vallejo
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain.
| | - Rémi Cousin
- BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France.
| | - María Muñoz-Caffarel
- Molecular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Jordi Llop
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Jean-Marie Piot
- BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France.
| | - Felix Elortza
- Proteomics Platform CIC bioGUNE, Bizkaia Science and Technology, Derio, Spain
| | - Thierry Maugard
- BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France.
| | - Jesús Ruiz-Cabello
- CIC biomaGUNE and Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Gipuzkoa, Spain. and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain and Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Madrid, Spain
| | - Ingrid Fruitier-Arnaudin
- BCBS team (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs Laboratory (Littoral environment et Sociétés), UMR CNRS 7266, University of La Rochelle, La Rochelle, France.
| |
Collapse
|
16
|
Larrea E, Fernandez-Mercado M, Guerra-Assunção JA, Wang J, Goicoechea I, Gaafar A, Ceberio I, Lobo C, Okosun J, Enright AJ, Fitzgibbon J, Lawrie CH. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma. Int J Mol Sci 2020; 21:ijms21228795. [PMID: 33233721 PMCID: PMC7699894 DOI: 10.3390/ijms21228795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 11/11/2020] [Accepted: 11/18/2020] [Indexed: 11/16/2022] Open
Abstract
Follicular lymphoma (FL) is a common indolent B-cell lymphoma that can transform into the more aggressive transformed FL (tFL). However, the molecular process driving this transformation is uncertain. In this work, we aimed to identify microRNA (miRNA)-binding sites recurrently mutated in follicular lymphoma patients, as well as in transformed FL patients. Using whole-genome sequencing data from FL tumors, we discovered 544 mutations located in bioinformatically predicted microRNA-binding sites. We then studied these specific regions using targeted sequencing in a cohort of 55 FL patients, found 16 recurrent mutations, and identified a further 69 variants. After filtering for QC, we identified 21 genes with mutated miRNA-binding sites that were also enriched for B-cell-associated genes by Gene Ontology. Over 40% of mutations identified in these genes were present exclusively in tFL patients. We validated the predicted miRNA-binding sites of five of the genes by luciferase assay and demonstrated that the identified mutations in BCL2 and EZH2 genes impaired the binding efficiency of miR-5008 and miR-144 and regulated the endogenous levels of messenger RNA (mRNA).
Collapse
Affiliation(s)
- Erika Larrea
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain; (E.L.); (M.F.-M.); (I.G.)
- Chinese Institute for Brain Research (CIBR), Beijing 102206, China
- School of Life Sciences, Tsinghua University, Beijing 100084, China
| | - Marta Fernandez-Mercado
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain; (E.L.); (M.F.-M.); (I.G.)
- Biomedical Engineering, School of Engineering, University of Navarra, 20014 San Sebastian, Spain
| | | | - Jun Wang
- Barts Cancer Institute, Queen Mary University of London, London EC1M 6BE, UK; (J.W.); (J.O.); (J.F.)
| | - Ibai Goicoechea
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain; (E.L.); (M.F.-M.); (I.G.)
- Multiple Myeloma Group, Centro de Investigación Médica Aplicada (CIMA), Pamplona, 31008 Navarra, Spain
| | - Ayman Gaafar
- Department of Pathology, Cruces Hospital, 48903 Bilbao, Spain;
| | - Izaskun Ceberio
- Hematology Department, Hospital Universitario Donostia, 20014 San Sebastián, Spain;
| | - Carmen Lobo
- Department of Pathology, Hospital Universitario Donostia, 20014 San Sebastián, Spain;
| | - Jessica Okosun
- Barts Cancer Institute, Queen Mary University of London, London EC1M 6BE, UK; (J.W.); (J.O.); (J.F.)
| | - Anton J. Enright
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK;
| | - Jude Fitzgibbon
- Barts Cancer Institute, Queen Mary University of London, London EC1M 6BE, UK; (J.W.); (J.O.); (J.F.)
| | - Charles H. Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain; (E.L.); (M.F.-M.); (I.G.)
- IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
- Radcliffe Department of Medicine, University of Oxford, Oxford OX4 3DU, UK
- Correspondence: ; Tel.: +34-943-006138
| |
Collapse
|
17
|
Casabonne D, Benavente Y, Seifert J, Costas L, Armesto M, Arestin M, Besson C, Hosnijeh FS, Duell EJ, Weiderpass E, Masala G, Kaaks R, Canzian F, Chirlaque MD, Perduca V, Mancini FR, Pala V, Trichopoulou A, Karakatsani A, La Vecchia C, Sánchez MJ, Tumino R, Gunter MJ, Amiano P, Panico S, Sacerdote C, Schmidt JA, Boeing H, Schulze MB, Barricarte A, Riboli E, Olsen A, Tjønneland A, Vermeulen R, Nieters A, Lawrie CH, de Sanjosé S. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. Int J Cancer 2020; 147:1315-1324. [PMID: 32012253 DOI: 10.1002/ijc.32894] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 11/18/2019] [Accepted: 12/17/2019] [Indexed: 12/16/2022]
Abstract
Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25-p75: 7-13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18-1.72), 1.64 (1.31-2.04) and 1.75 (1.31-2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve <0.62). hsa-miR-16-5p and hsa-miR-223-3p levels were unrelated to CLL risk. The findings of this first prospective study suggest that hsa-miR-29a, hsa-miR-150-5p and hsa-miR-155-5p were upregulated in early stages of CLL but were modest predictive biomarkers of CLL risk.
Collapse
MESH Headings
- Biomarkers, Tumor/blood
- Case-Control Studies
- Europe/epidemiology
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology
- Male
- MicroRNAs/blood
- Middle Aged
- Odds Ratio
- Predictive Value of Tests
- Prospective Studies
- Up-Regulation
Collapse
Affiliation(s)
- Delphine Casabonne
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - Yolanda Benavente
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - Julia Seifert
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Laura Costas
- Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - María Armesto
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - María Arestin
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Caroline Besson
- CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Gustave Roussy, Villejuif, France
- Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France
| | - Fatemeh S Hosnijeh
- Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
- Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Eric J Duell
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Elisabete Weiderpass
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Giovanna Masala
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - María-Dolores Chirlaque
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | - Vittorio Perduca
- CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Gustave Roussy, Villejuif, France
- Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France
- Laboratoire de Mathématiques Appliquées MAP5 (UMR CNRS 8145), Université Paris Descartes, Paris, France
| | - Francesca R Mancini
- CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Gustave Roussy, Villejuif, France
| | - Valeria Pala
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | | | - Anna Karakatsani
- Hellenic Health Foundation, Athens, Greece
- Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece
| | - Carlo La Vecchia
- Hellenic Health Foundation, Athens, Greece
- Dept. of Clinical Sciences and Community Health, Università Degli Studi di Milano, Milan, Italy
| | - Maria-Jose Sánchez
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Andalusian School of Public Health (EASP), Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain
| | - Rosario Tumino
- Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy
| | - Marc J Gunter
- Section of Nutrition and Metabolism, IARC, International Agency for Research on Cancer, Lyon, France
| | - Pilar Amiano
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Salvatore Panico
- Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, Città Della Salute e Della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
| | - Julie A Schmidt
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition (DIfE) Postdam-Rehbrücke, Nuthetal, Germany
| | - Matthias B Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
- Institute of Nutritional Sciences, University of Potsdam, Nuthetal, Germany
| | - Aurelio Barricarte
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Elio Riboli
- School of Public Health, Imperial College London, London, United Kingdom
| | - Anja Olsen
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Anne Tjønneland
- Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Public Health, The Copenhagen University, Copenhagen, Denmark
| | - Roel Vermeulen
- Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
| | - Alexandra Nieters
- Institute for Immunodeficiency (IFI) Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
- Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Silvia de Sanjosé
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
- Reproductive Health, PATH, Seattle, WA
| |
Collapse
|
18
|
Gerovska D, Larrinaga G, Solano-Iturri JD, Márquez J, García Gallastegi P, Khatib AM, Poschmann G, Stühler K, Armesto M, Lawrie CH, Badiola I, Araúzo-Bravo MJ. An Integrative Omics Approach Reveals Involvement of BRCA1 in Hepatic Metastatic Progression of Colorectal Cancer. Cancers (Basel) 2020; 12:E2380. [PMID: 32842712 PMCID: PMC7565528 DOI: 10.3390/cancers12092380] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/18/2020] [Accepted: 08/19/2020] [Indexed: 12/26/2022] Open
Abstract
(1) Background & Aims: The roles of different cells in the tumor microenvironment (TME) are critical to the metastatic process. The phenotypic transformation of the liver cells is one of the most important stages of the hepatic metastasis progression of colorectal cancer (CRC). Our aim was to identify the major molecules (i.e., genes, miRNAs and proteins) involved in this process. (2) Methods: We isolated and performed whole-genome analysis of gene, miRNA, and protein expression in three types of liver cells (Ito cells, Kupffer cells, and liver sinusoidal endothelial cells) from the TME of a murine model of CRC liver metastasis. We selected the statistically significant differentially expressed molecules using the Student's t-test with Benjamini-Hochberg correction and performed functional statistically-significant enrichment analysis of differentially expressed molecules with hypergeometric distribution using the curated collection of molecular signatures, MSigDB. To build a gene-miRNA-protein network centered in Brca1, we developed a software package (miRDiana) that collects miRNA targets from the union of the TargetScan, MicroCosm, mirTarBase, and miRWalk databases. This was used to search for miRNAs targeting Brca1. We validated the most relevant miRNAs with real-time quantitative PCR. To investigate BRCA1 protein expression, we built tissue microarrays (TMAs) from hepatic metastases of 34 CRC patients. (3) Results: Using integrated omics analyses, we observed that the Brca1 gene is among the twenty transcripts simultaneously up-regulated in all three types of TME liver cells during metastasis. Further analysis revealed that Brca1 is the last BRCA1-associated genome surveillance complex (BASC) gene activated in the TME. We confirmed this finding in human reanalyzing transcriptomics datasets from 184 patients from non-tumor colorectal tissue, primary colorectal tumor and colorectal liver metastasis of the GEO database. We found that the most probable sequence of cell activation during metastasis is Endothelial→Ito→Kupffer. Immunohistochemical analysis of human liver metastases showed the BRCA1 protein was co-localized in Ito, Kupffer, and endothelial cells in 81.8% of early or synchronous metastases. However, in the greater part of the metachronous liver metastases, this protein was not expressed in any of these TME cells. (4) Conclusions: These results suggest a possible role of the co-expression of BRCA1 in Ito, Kupffer, and sinusoidal endothelial cells in the early occurrence of CRC liver metastases, and point to BRCA1 as a potential TME biomarker.
Collapse
Affiliation(s)
- Daniela Gerovska
- Computational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, Calle Doctor Beguiristain s/n, 20014 San Sebastián, Spain;
- Computational Biomedicine Data Analysis Platform, Biodonostia Health Research Institute, Calle Doctor Beguiristain s/n, 20014 San Sebastián, Spain
| | - Gorka Larrinaga
- Department of Nursing I, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Bizkaia, Spain;
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Bizkaia, Spain
- BioCruces Health Research Institute, 48903 Barakaldo, Bizkaia, Spain;
| | - Jon Danel Solano-Iturri
- BioCruces Health Research Institute, 48903 Barakaldo, Bizkaia, Spain;
- Department of Anatomic Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), 48903 Barakaldo, Bizkaia, Spain
| | - Joana Márquez
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain; (J.M.); (P.G.G.)
| | - Patricia García Gallastegi
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain; (J.M.); (P.G.G.)
| | - Abdel-Majid Khatib
- University of Bordeaux, Allée Geoffroy St Hilaire, 33615 Pessac, France; INSERM, LAMC, UMR 1029, Allée Geoffroy St Hilaire, 33615 Pessac, France;
| | - Gereon Poschmann
- Institute of Molecular Medicine, Proteome Research, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany; (G.P.); (K.S.)
| | - Kai Stühler
- Institute of Molecular Medicine, Proteome Research, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany; (G.P.); (K.S.)
- Molecular Proteomics Laboratory, Biologisch-Medizinisches Forschungszentrum, Heinrich-Heine-University, 40225 Düsseldorf, Germany
| | - María Armesto
- Molecular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastián, Spain; (M.A.); (C.H.L.)
| | - Charles H. Lawrie
- Molecular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastián, Spain; (M.A.); (C.H.L.)
- Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
- IKERBASQUE, Basque Foundation for Science, Calle María Díaz Harokoa 3, 48013 Bilbao, Spain
| | - Iker Badiola
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain; (J.M.); (P.G.G.)
| | - Marcos J. Araúzo-Bravo
- Computational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, Calle Doctor Beguiristain s/n, 20014 San Sebastián, Spain;
- Computational Biomedicine Data Analysis Platform, Biodonostia Health Research Institute, Calle Doctor Beguiristain s/n, 20014 San Sebastián, Spain
- IKERBASQUE, Basque Foundation for Science, Calle María Díaz Harokoa 3, 48013 Bilbao, Spain
- CIBER of Frailty and Healthy Aging (CIBERfes), 28029 Madrid, Spain
- Computational Biology and Bioinformatics Group, Max Planck Institute for Molecular Biomedicine, Röntgenstr. 20, 48149 Münster, Germany
| |
Collapse
|
19
|
Auzmendi-Iriarte J, Saenz-Antoñanzas A, Mikelez-Alonso I, Carrasco-Garcia E, Tellaetxe-Abete M, Lawrie CH, Sampron N, Cortajarena AL, Matheu A. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis 2020; 11:417. [PMID: 32488056 PMCID: PMC7265429 DOI: 10.1038/s41419-020-2586-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 12/13/2022]
Abstract
Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacological target in cancer. In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more abundant in glioma stem cell subpopulation. Moreover, we identified a new small-molecule inhibitor of HDAC6, which presents strong sensitivity for HDAC6 inhibition and exerts high cytotoxic activity, alone or in combination with temozolomide. It is also able to significantly reduce tumor growth in vivo. Transcriptomic analysis of patient-derived glioma stem cells revealed an increase in cell differentiation and cell death pathways, as well as a decrease in cell-cycle activity and cell division by the treatment with the compound. Finally, the comparison with a pan-HDAC inhibitor, Vorinostat (SAHA), or HDAC6-specific inhibitor, Tubastatin A, showed higher target specificity and antitumor activity of the new HDAC6 inhibitor. In conclusion, our data reveal the efficacy of a novel HDAC6 inhibitor in glioblastoma preclinical setting.
Collapse
Affiliation(s)
| | | | - Idoia Mikelez-Alonso
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain
| | - Estefania Carrasco-Garcia
- Cellular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain.,CIBERfes, Carlos III Institute, Madrid, Spain
| | | | - Charles H Lawrie
- Molecular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.,Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Nicolás Sampron
- Cellular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain.,CIBERfes, Carlos III Institute, Madrid, Spain
| | - Aitziber L Cortajarena
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Ander Matheu
- Cellular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain. .,CIBERfes, Carlos III Institute, Madrid, Spain. .,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
| |
Collapse
|
20
|
Abstract
Metastasis, the development of secondary malignant growths at a distance from the primary site of a cancer, is associated with almost 90% of all cancer deaths, and half of all cancer patients present with some form of metastasis at the time of diagnosis. Consequently, there is a clear clinical need for a better understanding of metastasis. The role of miRNAs in the metastatic process is beginning to be explored. However, much is still to be understood. In this review, we present the accumulating evidence for the importance of miRNAs in metastasis as key regulators of this hallmark of cancer.
Collapse
Affiliation(s)
- Carla Solé
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain;
| | - Charles H. Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, 20014 San Sebastián, Spain;
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain
- Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
- Correspondence: or ; Tel.: +34-943-006138
| |
Collapse
|
21
|
Affiliation(s)
- Javier C Angulo
- Clinical Department, Faculty of Biomedical Sciences, European University of Madrid, Getafe, Madrid, Spain
| | - Charles H Lawrie
- Molecular Oncology, Biodonostia Research Institute, San Sebastián, Spain
| | - José I López
- Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Research Institute, University of the Basque Country (UPV/EHU), Leioa, Barakaldo, Spain
| |
Collapse
|
22
|
Wong KK, Lawrie CH, Green TM. Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. Biomark Insights 2019; 14:1177271919846454. [PMID: 31105426 PMCID: PMC6509988 DOI: 10.1177/1177271919846454] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2019] [Accepted: 04/05/2019] [Indexed: 12/28/2022] Open
Abstract
Epigenetic alteration has been proposed to give rise to numerous classic hallmarks of cancer. Impaired DNA methylation plays a central role in the onset and progression of several types of malignancies, and DNA methylation is mediated by DNA methyltransferases (DNMTs) consisting of DNMT1, DNMT3A, and DNMT3B. DNMTs are frequently implicated in the pathogenesis and aggressiveness of acute myeloid leukaemia (AML) patients. In this review, we describe and discuss the oncogenic roles of DNMT1, DNMT3A, and DNMT3B in AML. The clinical response predictive roles of DNMTs in clinical trials utilising hypomethylating agents (azacitidine and decitabine) in AML patients are presented. Novel hypomethylating agent (guadecitabine) and experimental DNMT inhibitors in AML are also discussed. In summary, hypermethylation of tumour suppressors mediated by DNMT1 or DNMT3B contributes to the progression and severity of AML (except MLL-AF9 and inv(16)(p13;q22) AML for DNMT3B), while mutation affecting DNMT3A represents an early genetic lesion in the pathogenesis of AML. In clinical trials of AML patients, expression of DNMTs is downregulated by hypomethylating agents while the clinical response predictive roles of DNMT biomarkers remain unresolved. Finally, nucleoside hypomethylating agents have continued to show enhanced responses in clinical trials of AML patients, and novel non-nucleoside DNMT inhibitors have demonstrated cytotoxicity against AML cells in pre-clinical settings.
Collapse
Affiliation(s)
- Kah Keng Wong
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia
| | - Charles H Lawrie
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.,Oncology Department, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Tina M Green
- Department of Pathology, Odense University Hospital, Odense, Denmark
| |
Collapse
|
23
|
Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH. The circulating transcriptome as a source of cancer liquid biopsy biomarkers. Semin Cancer Biol 2019; 58:100-108. [PMID: 30684535 DOI: 10.1016/j.semcancer.2019.01.003] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Revised: 01/16/2019] [Accepted: 01/22/2019] [Indexed: 02/07/2023]
Abstract
Non-invasive biomarkers or liquid biopsies have the potential to revolutionise cancer patient management as repeated sampling allows real-time monitoring of disease progression and response to treatment. This allows for earlier intervention and dynamic treatment management; both cornerstones of personalised medicine. The circulating transcriptome represents a rich source of potential cancer biomarkers that includes many classes of RNA, both coding and non-coding, that are only now beginning to be explored. In particular the increasing power and availability of RNAseq techniques have pushed studies beyond circulating miRNAs, to other classes of RNA including mRNA, snRNA, snoRNA, piRNA, YRNA, lncRNA and circRNA. In this review we focus on the emerging potential for these different classes of RNA as cancer biomarkers, and in particular the barriers and limitations that remain to be overcome if these molecules are to become part of routine clinical practice.
Collapse
Affiliation(s)
- Carla Sole
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain
| | - Esther Arnaiz
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain
| | - Lorea Manterola
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain
| | - David Otaegui
- Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain; Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom; IKERBASQUE, Basque Foundation for Science, María Díaz Haroko Kalea, 3, 48013, Bilbao, Spain.
| |
Collapse
|
24
|
Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez LI, Manterola L, Fernandez-Mercado M, Mujika K, Tuneu A, Jaka A, Tellaetxe M, Friedländer MR, Estivill X, Piazza P, Ortiz-Romero PL, Middleton MR, Lawrie CH. The Circulating Transcriptome as a Source of Biomarkers for Melanoma. Cancers (Basel) 2019; 11:cancers11010070. [PMID: 30634628 PMCID: PMC6356785 DOI: 10.3390/cancers11010070] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 01/02/2019] [Accepted: 01/04/2019] [Indexed: 12/18/2022] Open
Abstract
The circulating transcriptome is a valuable source of cancer biomarkers, which, with the exception of microRNAs (miRNAs), remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients from healthy individuals, we used next generation sequencing (NGS), and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed (p < 0.05). Levels of miR-134-5p and miR-320a-3p were significantly down-regulated (p < 0.001) in melanoma samples (n = 96) compared to healthy controls (n = 28). Differentially expressed protein-encoding mRNA 5'-fragments were enriched for the angiopoietin, p21-activated kinase (PAK), and EIF2 pathways. Levels of ATM1, AMFR, SOS1, and CD109 gene fragments were up-regulated (p < 0.001) in melanoma samples (n = 144) compared to healthy controls (n = 41) (AUC = 0.825). Over 40% of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of RNY3P1, RNY4P1, and RNY4P25 were significantly higher in patients with stage 0 disease than either healthy controls or more advanced stage disease (p < 0.001). In conclusion, we have identified a number of novel RNA biomarkers, which, most importantly, we validated in multi-center retrospective and prospective cohorts, suggesting potential diagnostic use of these RNA species.
Collapse
Affiliation(s)
- Carla Solé
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | - Daniela Tramonti
- Department of Oncology, University of Oxford, Oxford OX3 9DU, UK.
| | - Maike Schramm
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
- Faculty of Biosciences, University of Heidelberg, Heidelberg 69120, Germany.
| | - Ibai Goicoechea
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | - María Armesto
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | - Luiza I Hernandez
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | - Lorea Manterola
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | | | - Karmele Mujika
- Onkologikoa-Oncology Institute Gipuzkoa, Gipuzkoa 20012, Spain.
| | - Anna Tuneu
- Department of Dermatology, Hospital Universitario de Donostia, San Sebastian 20012, Spain.
| | - Ane Jaka
- Department of Dermatology, Hospital Universitario de Donostia, San Sebastian 20012, Spain.
| | - Maitena Tellaetxe
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
| | - Marc R Friedländer
- Genomics and Disease group, Centre for Genomic Regulation (CRG), Barcelona 08003, Spain.
- Universitat Pompeu Fabra (UPF), Barcelona 08002, Spain.
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Barcelona 08002, Spain.
- Hospital del Mar Research Institute (IMIM), Barcelona 08003, Spain.
- Science for Life Laboratory, The Wenner-Gren Institute, Stockholm University, Stockholm SE-106 9, Sweden.
| | - Xavier Estivill
- Genomics and Disease group, Centre for Genomic Regulation (CRG), Barcelona 08003, Spain.
- Universitat Pompeu Fabra (UPF), Barcelona 08002, Spain.
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Barcelona 08002, Spain.
- Hospital del Mar Research Institute (IMIM), Barcelona 08003, Spain.
| | - Paolo Piazza
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
- Imperial BRC Genomics Facility, Imperial College London, London SW7 2AZ, UK.
| | - Pablo L Ortiz-Romero
- Department of Dermatology, 12 de Octubre Hospital, Madrid 28041, Spain.
- Medical School, Universidad Complutense, Institute i+12, Centro de Investigación Biomédica en Red en Oncologia (CIBERONC), Madrid 28040, Spain.
| | - Mark R Middleton
- Department of Oncology, University of Oxford, Oxford OX3 9DU, UK.
| | - Charles H Lawrie
- Molecular Oncology group, Biodonostia Research Institute, San Sebastián 20012, Spain.
- Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.
- IKERBASQUE, Basque Foundation for Science, Bilbao 48013, Spain.
| |
Collapse
|
25
|
Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH. CircRNAs and cancer: Biomarkers and master regulators. Semin Cancer Biol 2018; 58:90-99. [PMID: 30550956 DOI: 10.1016/j.semcancer.2018.12.002] [Citation(s) in RCA: 269] [Impact Index Per Article: 44.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 11/30/2018] [Accepted: 12/10/2018] [Indexed: 02/06/2023]
Abstract
Circular RNAs (circRNAs) are a novel class of regulatory RNAs that despite being relatively abundant have only recently begun to be explored. There are many thousands of genes that appear capable of producing circRNAs, however the function of all but a handful remain to be determined. What is emerging about these highly conserved molecules is that they play important roles in biology and cancer biology in particular. The most explored function of circRNAs is as master regulators of gene expression that act to sequester or ´sponge´ other gene expression regulators, in particular miRNAs. They have also been demonstrated to function via direct modulation of transcription, and by interfering with splicing mechanisms. Although generally expressed in low abundance when compared to their linear counterparts, they are often expressed in a tissue- and developmental stage- specific manner. Coupled with their remarkable resistance to RNAse activity due to a covalent closed cyclic structure, circRNAs show great promise as novel biomarkers of cancer and other diseases. In this review we consider the current state of knowledge regarding these molecules, their synthesis, function, and association with cancer. We will also review some of the challenges that remain to be resolved if this emerging class of RNAs are really to become useful in the clinic.
Collapse
Affiliation(s)
- Esther Arnaiz
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain
| | - Carla Sole
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain
| | - Lorea Manterola
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain
| | - Leire Iparraguirre
- Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain
| | - David Otaegui
- Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n San Sebastián, 20014, Spain; Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom; IKERBASQUE, Basque Foundation for Science, María Díaz Haroko Kalea, 3, 48013, Bilbao, Spain.
| |
Collapse
|
26
|
Abstract
B-cell lymphomas represent a diverse group of neoplasms classified primarily by histopatholgy and are often challenging to accurately diagnose. Despite having been recognized less than 20 years ago, microRNAs (miRNAs) have emerged as one of the most promising class of cancer molecular biomarkers and are particularly attractive as they can be readily detected in formalin-fixed paraffin-embedded biopsy material and biological fluids such as blood. Many of the identified B-cell lymphoma miRNA biomarkers also play crucial regulatory roles in normal B-cell development. Below we consider the identity, function, and biomarker potential of miRNAs in B-cell lymphoma and most importantly the barriers that remain to be overcome if they are really to become part of routine clinical practice.
Collapse
Affiliation(s)
- Carla Solé
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Esther Arnaiz
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain
| | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain.,Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
27
|
López JI, Pulido R, Cortés JM, Angulo JC, Lawrie CH. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathol Res Pract 2018; 214:1110-1114. [PMID: 29910061 DOI: 10.1016/j.prp.2018.06.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 06/07/2018] [Accepted: 06/08/2018] [Indexed: 11/19/2022]
Abstract
Intratumor heterogeneity (ITH) detection remains a challenge in modern oncology because it can have a direct impact on the success of new therapies. Anti-PD-1/PD-L1 immunotherapy is an emerging treatment modality that is showing great promise for clear cell renal cell carcinoma (CCRCC) patients with advanced disease. Patient selection for such therapy relies upon the immunohistochemical detection of PD-1/PD-L1, however the degree of ITH for these markers among tumor cells and/or inflammatory mononuclear infiltrates remains unknown. Therefore, we analyzed PD-L1 (SP-142) expression in the tumor inflammatory cells of 22 CCRCC cases with the aim to define the pattern of PD-L1 expression, and to compare the reliability of current tumor sampling protocols (RS) with a multisite tumor sampling strategy (MSTS). While the RS protocol identified 5/22 (22.7%) of cases that were positive for PD-L1 expression, MSTS identified 10/22 (45.45%) of cases. This suggests that RS may miss a proportion of CCRCC patients that might benefit from immunotherapy. In addition, MSTS demonstrated that positive and negative regions of PD-L1 expression are very variable within each tumor.
Collapse
Affiliation(s)
- José I López
- Department of Pathology, Cruces University Hospital, Barakaldo, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; Department of Medical-Surgical Specialties, University of the Basque Country (UPV/EHU), Leioa, Spain.
| | - Rafael Pulido
- Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain
| | - Jesús M Cortés
- IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain; Quantitative Biomedicine Unit, Biocruces Research Institute, Barakaldo, Spain; Department of Cell Biology and Histology, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - Javier C Angulo
- Department of Urology, University Hospital of Getafe, Getafe, Madrid, Spain; Clinical Department, European University of Madrid, Laureate Universities, Madrid, Spain
| | - Charles H Lawrie
- IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain; Molecular Oncology, Biodonostia Research Institute, Donostia-San Sebastián, Spain; Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain; Radcliffe Department of Medicine, University of Oxford, UK
| |
Collapse
|
28
|
López JI, Pulido R, Lawrie CH, Angulo JC. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. Ann Diagn Pathol 2018; 34:89-93. [PMID: 29661736 DOI: 10.1016/j.anndiagpath.2018.03.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 03/13/2018] [Accepted: 03/23/2018] [Indexed: 12/19/2022]
Abstract
Immunotherapy is a promising tool in the treatment of patients with advancer renal cancer, in particular the blockage of immune checkpoint inhibitors. Clear cell renal cell carcinoma is an example of heterogeneous neoplasm and this particular characteristic is responsible of many therapeutic failures so far. Since variations in the local microenvironment across a tumor may conditionate the effect of this new therapy, a deeper knowledge of this issue seems advisable for any treatment success. We have analyzed the PD-L1 (SP142) expression in three different areas in the tumor and in two areas in the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas to determine the extent and potential clinical significance of this regional variability. A statistically significant decrease in PD-L1 expression has been detected between the main tumor and its thrombus faction (p < 0.0001). Also, we have observed a high variability in the PD-L1 positivity across the three different areas of the main tumor tested, with only three cases being uniformly positive in all tested areas. In conclusion, PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy.
Collapse
Affiliation(s)
- José I López
- Department of Pathology, Cruces University Hospital, Barakaldo, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; Department of Medical-Surgical Specialties, University of the Basque Country (UPV/EHU), Leioa, Spain.
| | - Rafael Pulido
- Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain
| | - Charles H Lawrie
- IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain; Molecular Oncology, Biodonostia Research Institute, Donostia-San Sebastián, Spain; Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain; Radcliffe Department of Medicine, University of Oxford, UK
| | - Javier C Angulo
- Service of Urology, University Hospital of Getafe, Getafe, Madrid, Spain; Clinical Department, European University of Madrid, Laureate Universities, Madrid, Spain
| |
Collapse
|
29
|
Guarch R, Lawrie CH, Larrinaga G, Angulo JC, Pulido R, López JI. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma. Ann Diagn Pathol 2018; 34:27-30. [PMID: 29661723 DOI: 10.1016/j.anndiagpath.2018.01.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Accepted: 01/08/2018] [Indexed: 12/18/2022]
Abstract
Immunohistochemistry is a basic routine in establishing the diagnosis of many tumors. However, immunomarkers are often irregularly distributed across different regions of the same tumor, alternating positive and negative areas without any apparent cause. Full identification of this type of intratumor heterogeneity is crucial for patients since the expression of many markers is linked to the prognosis and/or treatment of some tumors. We have quantified this variability testing 406 tumor samples from eight clear cell renal cell carcinomas using four epithelial-mesenchymal transition markers (vimentin, ZEB-1, β-catenin, and E-cadherin) and two different sampling protocols. Routine sampling included an amount of 59 samples (average, 7.3 samples/case) and multisite tumor sampling did a total of 347 samples (average, 43.3 samples/case). High variability of immunostaining was detected with E-cadherin and ZEB-1 in all high-grade cases. Irregular patterns of expression were detected in all tumors including all histologically homogeneous low-grade tumors. Multisite tumor sampling protocol detected a significant decreased number of E-cadherin, β-catenin and ZEB-1 positive samples in high-grade tumors. We conclude that high levels of intratumor heterogeneity characterize the immunohistochemical expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinomas. Multisite tumor sampling protocol outperforms routine sampling in detecting immunohistochemical intratumor heterogeneity.
Collapse
Affiliation(s)
- Rosa Guarch
- Department of Pathology, Complejo Hospitalario B de Navarra, Pamplona, Navarra, Spain
| | - Charles H Lawrie
- Onco-hematology Unit, Biodonostia Research Institute, Donostia-San Sebastián, Spain; Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain; Nuffield Department of Clinical Laboratory Sciences, University of Oxford, UK; IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain
| | - Gorka Larrinaga
- Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain; Department of Nursing I, University of the Basque Country (UPV/EHU), Leioa, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain
| | - Javier C Angulo
- Department of Urology, Getafe University Hospital, Getafe, Madrid, Spain; Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Laureate Universities, Madrid, Spain
| | - Rafael Pulido
- IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; Department of Cellular Biology and Histology, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - José I López
- Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, Spain; Department of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, Spain.
| |
Collapse
|
30
|
Lawrie CH, Armesto M, Fernandez-Mercado M, Arestín M, Manterola L, Goicoechea I, Larrea E, Caffarel MM, Araujo AM, Sole C, Sperga M, Alvarado-Cabrero I, Michal M, Hes O, López JI. Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. J Mol Diagn 2018; 20:34-45. [PMID: 29056573 DOI: 10.1016/j.jmoldx.2017.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 08/29/2017] [Accepted: 09/13/2017] [Indexed: 01/23/2023] Open
Abstract
Tubulocystic renal cell carcinoma (TC-RCC) is a rare recently described renal neoplasm characterized by gross, microscopic, and immunohistochemical differences from other renal tumor types and was recently classified as a distinct entity. However, this distinction remains controversial particularly because some genetic studies suggest a close relationship with papillary RCC (PRCC). The molecular basis of this disease remains largely unexplored. We therefore performed noncoding (nc) RNA/miRNA expression analysis and targeted next-generation sequencing mutational profiling on 13 TC-RCC cases (11 pure, two mixed TC-RCC/PRCC) and compared with other renal neoplasms. The expression profile of miRNAs and other ncRNAs in TC-RCC was distinct and validated 10 differentially expressed miRNAs by quantitative RT-PCR, including miR-155 and miR-34a, that were significantly down-regulated compared with PRCC cases (n = 22). With the use of targeted next-generation sequencing we identified mutations in 14 different genes, most frequently (>60% of TC-RCC cases) in ABL1 and PDFGRA genes. These mutations were present in <5% of clear cell RCC, PRCC, or chromophobe RCC cases (n > 600) of The Cancer Genome Atlas database. In summary, this study is by far the largest molecular study of TC-RCC cases and the first to investigate either ncRNA expression or their genomic profile. These results add molecular evidence that TC-RCC is indeed a distinct entity from PRCC and other renal neoplasms.
Collapse
Affiliation(s)
- Charles H Lawrie
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
| | - María Armesto
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | | | - María Arestín
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - Lorea Manterola
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - Ibai Goicoechea
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - Erika Larrea
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - María M Caffarel
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Angela M Araujo
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - Carla Sole
- Molecular Oncology Group of Biodonostia Research Institute, San Sebastian, Spain
| | - Maris Sperga
- Department of Pathology, Riga Stradins University, Riga, Latvia
| | | | - Michal Michal
- Department of Pathology, Charles University Hospital, Plzen, Czech Republic
| | - Ondrej Hes
- Department of Pathology, Charles University Hospital, Plzen, Czech Republic
| | - José I López
- Department of Pathology, Cruces University Hospital, University of the Basque Country, Barakaldo, Bizkaia, Spain; BioCruces Research Institute, Barakaldo, Bizkaia, Spain
| |
Collapse
|
31
|
Aboudzadeh MA, Sanromán-Iglesias M, Lawrie CH, Grzelczak M, Liz-Marzán LM, Schäfer T. Blocking probe as a potential tool for detection of single nucleotide DNA mutations: design and performance. Nanoscale 2017; 9:16205-16213. [PMID: 29043363 DOI: 10.1039/c7nr06675a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Developing strategies to detect single nucleotide DNA mutations associated with treatment decisions in cancer patients from liquid biopsies is a rapidly emerging area of personalized medicine that requires high specificity. Here we report how to design an easy enzyme-free approach that could create a platform for detection of L858R mutation of EGFR that is a predictive biomarker of tyrosine kinase treatment in many cancers. This approach includes the addition of blocking probes with the antisense ssDNA at different blocking positions and different concentrations such as to avoid re-annealing with the respective sense ssDNA. The successful blocking strategy was corroborated by fluorescence spectroscopy in solution using two distinct FRET pairs and quartz crystal microbalance with dissipation (QCM-D) measurements under comparable experimental conditions, as the hybridization rate-limiting step in both methods is the nucleation process. The efficiency of hybridization of each blocking probe was strongly dependent on its position particularly when the analyte possesses a secondary hairpin-structure. We tested the performance of blocking probes in combination with gold nanoparticles; the obtained results were in agreement with those of QCM-D. These findings could facilitate the development of better biosensors, especially those using probes containing secondary structure.
Collapse
Affiliation(s)
- M Ali Aboudzadeh
- Polymat, University of the Basque Country, 20018 Donostia-San Sebastián, Spain.
| | | | | | | | | | | |
Collapse
|
32
|
Loo SK, Ch'ng ES, Lawrie CH, Muruzabal MA, Gaafar A, Pomposo MP, Husin A, Md Salleh MS, Banham AH, Pedersen LM, Møller MB, Green TM, Wong KK. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. Pathology 2017; 49:731-739. [PMID: 29074044 DOI: 10.1016/j.pathol.2017.08.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2017] [Revised: 08/16/2017] [Accepted: 08/20/2017] [Indexed: 11/26/2022]
Abstract
DNMT1 is a target of approved anti-cancer drugs including decitabine. However, the prognostic value of DNMT1 protein expression in R-CHOP-treated diffuse large B-cell lymphomas (DLBCLs) remains unexplored. Here we showed that DNMT1 was expressed in the majority of DLBCL cases (n = 209/230, 90.9%) with higher expression in germinal centre B-cell-like (GCB)-DLBCL subtype. Low and negative DNMT1 expression (20% cut-off, n = 33/230, 14.3%) was predictive of worse overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001). Nonetheless, of the 209 DNMT1 positive patients, 33% and 42% did not achieve 5-year OS and PFS, respectively, indicating that DNMT1 positive patients showed considerably heterogeneous outcomes. Moreover, DNMT1 was frequently expressed in mitotic cells and significantly correlated with Ki-67 or BCL6 expression (r = 0.60 or 0.44, respectively; p < 0.001). We demonstrate that DNMT1 is predictive of DLBCL patients' survival, and suggest that DNMT1 could be a DLBCL therapeutic target due to its significant association with Ki-67.
Collapse
Affiliation(s)
- Suet Kee Loo
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Ewe Seng Ch'ng
- Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Kepala Batas, Pulau Pinang, Malaysia
| | - Charles H Lawrie
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; Oncology Department, Biodonostia Research Institute, San Sebastian, Spain
| | | | - Ayman Gaafar
- Department of Pathology, Hospital Universitario Cruces, Barakaldo, Spain
| | | | - Azlan Husin
- Department of Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Md Salzihan Md Salleh
- Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Alison H Banham
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
| | - Lars M Pedersen
- Department of Haematology, Herlev University Hospital, Copenhagen, Denmark
| | - Michael B Møller
- Department of Pathology, Odense University Hospital, Odense, Denmark
| | - Tina M Green
- Department of Pathology, Odense University Hospital, Odense, Denmark
| | - Kah Keng Wong
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
| |
Collapse
|
33
|
Goicoechea I, Rezola R, Arestin M, M Caffarel M, Cortazar AR, Manterola L, Fernandez-Mercado M, Armesto M, Sole C, Larrea E, M Araujo A, Ancizar N, Plazaola A, Urruticoechea A, Carracedo A, Ruiz I, Alvarez Lopez I, H Lawrie C. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. F1000Res 2017; 6:1606. [PMID: 29862012 PMCID: PMC5843846 DOI: 10.12688/f1000research.12393.2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/13/2018] [Indexed: 01/14/2023] Open
Abstract
Background: The outcome for oestrogen receptor positive (ER+) breast cancer patients has improved greatly in recent years largely due to targeted therapy. However, the presence of involved multiple synchronous lymph nodes remains associated with a poor outcome. Consequently, these patients would benefit from the identification of new prognostic biomarkers and therapeutic targets. The expression of G-protein-coupled receptor kinase-interacting protein 1 (GIT1) has recently been shown to be an indicator of advanced stage breast cancer. Therefore, we investigated its expression and prognostic value of GIT1 in a cohort of 140 ER+ breast cancer with synchronous lymph node involvement. Methods: Immunohistochemistry was employed to assess GIT1 expression in a tissue microarray (TMA) containing duplicate non-adjacent cores with matched primary tumour and lymph node tissue (n=140). GIT1 expression in tumour cells was scored and statistical correlation analyses were carried out. Results: The results revealed a sub-group of patients that displayed discordant expression of GIT1 between the primary tumour and the lymph nodes (i.e. spatial intratumoural heterogeneity). We observed that loss of GIT1 expression in the tumour cells of the metastasis was associated with a shorter time to recurrence, poorer overall survival, and a shorter median survival time. Moreover, multivariate analysis demonstrated that GIT1 expression was an independent prognostic indicator. Conclusions: GIT1 expression enabled the identification of a sub-class of ER+ patients with lymph node metastasis that have a particularly poor prognostic outcome. We propose that this biomarker could be used to further stratify ER+ breast cancer patients with synchronous lymph node involvement and therefore facilitate adjuvant therapy decision making.
Collapse
Affiliation(s)
- Ibai Goicoechea
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - Ricardo Rezola
- Department of Pathology and Anatomy, Onkologikoa- Instituto Oncológico, San Sebastián, 20014, Spain
| | - María Arestin
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - María M Caffarel
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, 48013, Spain
| | | | - Lorea Manterola
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | | | - María Armesto
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - Carla Sole
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - Erika Larrea
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - Angela M Araujo
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain
| | - Nerea Ancizar
- Oncology Department, University Hospital Donostia, San Sebastián, 20014, Spain
| | - Arrate Plazaola
- Onkologikoa- Instituto Oncológico, San Sebastián, 20014, Spain
| | | | - Arkaitz Carracedo
- IKERBASQUE, Basque Foundation for Science, Bilbao, 48013, Spain.,CIC bioGUNE, Derio, 48160, Spain.,Department of Biochemistry and Molecular Biology, University of the Basque Country, Leioa , 48940, Spain
| | - Irune Ruiz
- Department of Pathology and Anatomy, University Hospital Donostia, San Sebastián, 20014, Spain
| | | | - Charles H Lawrie
- Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, 20014, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, 48013, Spain.,Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK
| |
Collapse
|
34
|
Sanromán-Iglesias M, Lawrie CH, Liz-Marzán LM, Grzelczak M. Nanoparticle-Based Discrimination of Single-Nucleotide Polymorphism in Long DNA Sequences. Bioconjug Chem 2017; 28:903-906. [DOI: 10.1021/acs.bioconjchem.7b00028] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- María Sanromán-Iglesias
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Oncology
Area, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
| | - Charles H. Lawrie
- Oncology
Area, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Luis M. Liz-Marzán
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 20014 Donostia-San
Sebastián, Spain
| | - Marek Grzelczak
- CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 20014 Donostia-San
Sebastián, Spain
| |
Collapse
|
35
|
Lawrie CH. MicroRNA master regulator of hematopoiesis may also hold the key to B-cell lymphoma pathogenesis and therapy. Transl Cancer Res 2016. [DOI: 10.21037/tcr.2016.10.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
36
|
Sanromán-Iglesias M, Lawrie CH, Schäfer T, Grzelczak M, Liz-Marzán LM. Sensitivity Limit of Nanoparticle Biosensors in the Discrimination of Single Nucleotide Polymorphism. ACS Sens 2016. [DOI: 10.1021/acssensors.6b00393] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- María Sanromán-Iglesias
- CIC biomaGUNE, Paseo de Miramón
182, 20009 Donostia-San
Sebastián, Spain
- Molecular
Oncology Group, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
| | - Charles H. Lawrie
- Molecular
Oncology Group, Biodonostia Research Institute, 20014 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Thomas Schäfer
- Polymat, University of the Basque Country, 20018 Donostia-San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Marek Grzelczak
- CIC biomaGUNE, Paseo de Miramón
182, 20009 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 20009 Donostia-San
Sebastián, Spain
| | - Luis M. Liz-Marzán
- CIC biomaGUNE, Paseo de Miramón
182, 20009 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 20009 Donostia-San
Sebastián, Spain
| |
Collapse
|
37
|
Santos JC, Carrasco-Garcia E, Garcia-Puga M, Aldaz P, Montes M, Fernandez-Reyes M, de Oliveira CC, Lawrie CH, Araúzo-Bravo MJ, Ribeiro ML, Matheu A. SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Cancer Res 2016; 76:6735-6746. [PMID: 27569216 DOI: 10.1158/0008-5472.can-16-1120] [Citation(s) in RCA: 92] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 08/16/2016] [Accepted: 08/18/2016] [Indexed: 11/16/2022]
Abstract
Gastric cancer remains one of the leading causes of global cancer mortality due to therapy resistance, with Helicobacter pylori (H. pylori) infection being a major risk factor. In this study, we report the significance of an elevation of the stem cell regulator SOX9 in bacteria-infected human gastritis and cancer samples, paralleling increased levels of TNFα SOX9 elevation was more intense in specimens containing the pathogenically significant cagA+ strains of H. pylori Notably, we found that SOX9 was required for bacteria-induced gastric cancer cell proliferation, increased levels of β-catenin, and acquisition of stem cell-like properties. Analysis of three large clinical cohorts revealed elevated SOX9 levels in gastric cancer with advanced tumor stage and poor patient survival. Functionally, SOX9 silencing in gastric cancer cells enhanced apoptosis and senescence, concomitantly with a blockade to self-renewal and tumor-initiating capability. Paralleling these effects, we also found SOX9 to mediate cisplatin chemoresistance associated with reduced disease-free survival. Mechanistic interactions between SOX9 and β-catenin expression suggested the existence of a regulatory role for SOX9 targeting the WNT canonical pathway. Taken together, our findings establish the significance of SOX9 in gastric cancer pathobiology and heterogeneity, with implications for targeting WNT-SOX9 signaling as a rational therapeutic strategy. Cancer Res; 76(22); 6735-46. ©2016 AACR.
Collapse
Affiliation(s)
- Juliana Carvalho Santos
- Unidade Integrada de Farmacologia e Gastroenterologia, Universidade São Francisco, Bragança Paulista, São Paulo, Brazil.,Programa de Pos Graduação em Genetica e Biologia Molecular, State University of Campinas, Campinas, São Paulo, Brazil
| | | | - Mikel Garcia-Puga
- Neuro-oncology group, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Paula Aldaz
- Neuro-oncology group, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Milagrosa Montes
- Microbiology Service, Biodonostia Health Research Institute and Hospital Donostia, San Sebastian, Spain
| | - Maria Fernandez-Reyes
- Microbiology Service, Biodonostia Health Research Institute and Hospital Donostia, San Sebastian, Spain
| | - Caroline Candida de Oliveira
- Unidade Integrada de Farmacologia e Gastroenterologia, Universidade São Francisco, Bragança Paulista, São Paulo, Brazil
| | - Charles H Lawrie
- IKERBASQUE Basque Foundation for Science, Bilbao, Spain.,Molecular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Marcos J Araúzo-Bravo
- IKERBASQUE Basque Foundation for Science, Bilbao, Spain.,Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebastian, Spain
| | - Marcelo Lima Ribeiro
- Unidade Integrada de Farmacologia e Gastroenterologia, Universidade São Francisco, Bragança Paulista, São Paulo, Brazil. .,Programa de Pos Graduação em Genetica e Biologia Molecular, State University of Campinas, Campinas, São Paulo, Brazil
| | - Ander Matheu
- Neuro-oncology group, Biodonostia Health Research Institute, San Sebastian, Spain. .,IKERBASQUE Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
38
|
Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, dM Vivanco M, Matheu A, Gomis RR, Carracedo A. Stratification and therapeutic potential of PML in metastatic breast cancer. Nat Commun 2016; 7:12595. [PMID: 27553708 PMCID: PMC4999521 DOI: 10.1038/ncomms12595] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 07/12/2016] [Indexed: 01/15/2023] Open
Abstract
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
Collapse
Affiliation(s)
| | - Marco Piva
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Jelena Urosevic
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Paula Aldaz
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
| | | | | | - Leire Arreal
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Verónica Torrano
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Ana R. Cortazar
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Evarist Planet
- Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
| | - Marc Guiu
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Nina Radosevic-Robin
- ERTICa Research Group, University of Auvergne EA4677, Clermont-Ferrand, France
- Biodiagnostics Laboratory OncoGenAuvergne, Pathology Unit, Jean Perrin Comprehensive Cancer Center, 63000 Clermont-Ferrand, France
| | - Stephane Garcia
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France
| | - Iratxe Macías
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Fernando Salvador
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Giacomo Domenici
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Oscar M. Rueda
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
| | | | | | | | | | | | | | - Marta Varela-Rey
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Maria Luz Martínez-Chantar
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Juan Anguita
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Yasir H. Ibrahim
- Experimental Therapeutics Group, Vall d'Hebron University Hospital, 08035 Barcelona, Spain
- Weill Cornell Medicine, New York 10021, USA
| | - Maurizio Scaltriti
- Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 10065 New York, USA
| | - Charles H. Lawrie
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Ana M. Aransay
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Juan L. Iovanna
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France
| | - Jose Baselga
- Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 New York, USA
| | - Carlos Caldas
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
| | - Rosa Barrio
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Maria dM Vivanco
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Ander Matheu
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Roger R. Gomis
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Arkaitz Carracedo
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
- Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), 48949 Leioa, Spain
| |
Collapse
|
39
|
Guarch R, Cortés JM, Lawrie CH, López JI. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Res 2016; 5:2020. [PMID: 27635226 PMCID: PMC5007747 DOI: 10.12688/f1000research.9419.2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/15/2016] [Indexed: 12/23/2022] Open
Abstract
Current standard-of-care tumor sampling protocols for CCRCC (and other cancers) are not efficient at detecting intratumoural heterogeneity (ITH). We have demonstrated in silico that an alternative protocol, multi-site tumor sampling (MSTS) based upon the divide and conquer (DAC) algorithm, can significantly increase the efficiency of ITH detection without extra costs. Now we test this protocol on routine hematoxylin-eosin (HE) sections in a series of 38 CCRCC cases. MSTS was found to outperform traditional sampling when detecting either high grade (p=0.0136) or granular/eosinophilic cells (p=0.0114). We therefore propose that MSTS should be used in routine clinical practice.
Collapse
Affiliation(s)
- Rosa Guarch
- Department of Pathology, Complejo Hospitalario B de Navarra, Pamplona, Navarra, 31008, Spain
| | - Jesús M Cortés
- Quantitative Biomedicine Unit, Biocruces Research Institute, Barakaldo, 48903, Spain; Ikerbasque: The Basque Foundation for Science, Bilbao, 48013, Spain; Department of Cell Biology and Histology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain
| | - Charles H Lawrie
- Ikerbasque: The Basque Foundation for Science, Bilbao, 48013, Spain; Molecular Oncology Group, Biodonostia Research Institute, San Sebastian, 20014, Spain; Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain; Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK
| | - José I López
- Department of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, 48903, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, 48903, Spain
| |
Collapse
|
40
|
Guarch R, Cortés JM, Lawrie CH, López JI. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Res 2016. [PMID: 27635226 DOI: 10.12688/f1000research.9419.1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Current standard-of-care tumor sampling protocols for CCRCC (and other cancers) are not efficient at detecting intratumoural heterogeneity (ITH). We have demonstrated in silico that an alternative protocol, multi-site tumor sampling (MSTS) based upon the divide and conquer (DAC) algorithm, can significantly increase the efficiency of ITH detection without extra costs. Now we test this protocol on routine hematoxylin-eosin (HE) sections in a series of 38 CCRCC cases. MSTS was found to outperform traditional sampling when detecting either high grade (p=0.0136) or granular/eosinophilic cells (p=0.0114). We therefore propose that MSTS should be used in routine clinical practice.
Collapse
Affiliation(s)
- Rosa Guarch
- Department of Pathology, Complejo Hospitalario B de Navarra, Pamplona, Navarra, 31008, Spain
| | - Jesús M Cortés
- Quantitative Biomedicine Unit, Biocruces Research Institute, Barakaldo, 48903, Spain; Ikerbasque: The Basque Foundation for Science, Bilbao, 48013, Spain; Department of Cell Biology and Histology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain
| | - Charles H Lawrie
- Ikerbasque: The Basque Foundation for Science, Bilbao, 48013, Spain; Molecular Oncology Group, Biodonostia Research Institute, San Sebastian, 20014, Spain; Department of Physiology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain; Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK
| | - José I López
- Department of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, 48903, Spain; Biomarkers in Cancer Unit, Biocruces Research Institute, Barakaldo, 48903, Spain
| |
Collapse
|
41
|
Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel MM, Araujo AM, Araiz M, Fernandez-Mercado M, Lawrie CH. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci 2016; 17:ijms17050627. [PMID: 27128908 PMCID: PMC4881453 DOI: 10.3390/ijms17050627] [Citation(s) in RCA: 174] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2016] [Revised: 04/18/2016] [Accepted: 04/18/2016] [Indexed: 12/19/2022] Open
Abstract
The effective and efficient management of cancer patients relies upon early diagnosis and/or the monitoring of treatment, something that is often difficult to achieve using standard tissue biopsy techniques. Biological fluids such as blood hold great possibilities as a source of non-invasive cancer biomarkers that can act as surrogate markers to biopsy-based sampling. The non-invasive nature of these “liquid biopsies” ultimately means that cancer detection may be earlier and that the ability to monitor disease progression and/or treatment response represents a paradigm shift in the treatment of cancer patients. Below, we review one of the most promising classes of circulating cancer biomarkers: microRNAs (miRNAs). In particular, we will consider their history, the controversy surrounding their origin and biology, and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.
Collapse
Affiliation(s)
- Erika Larrea
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - Carla Sole
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - Lorea Manterola
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - Ibai Goicoechea
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - María Armesto
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - María Arestin
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - María M Caffarel
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.
| | - Angela M Araujo
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
| | - María Araiz
- Hematology Department, Donostia Hospital, 20014 San Sebastián, Spain.
| | | | - Charles H Lawrie
- Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain.
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.
- Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford OX3 9DU, UK.
| |
Collapse
|
42
|
Fernandez-Mercado M, Manterola L, Lawrie CH. MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. Curr Genomics 2016; 16:349-58. [PMID: 27047255 PMCID: PMC4763973 DOI: 10.2174/1389202916666150707160147] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 04/20/2015] [Accepted: 04/22/2015] [Indexed: 12/19/2022] Open
Abstract
Although it is now evident that microRNAs (miRNAs) play a critical regulatory role in many, if not all, pathological and physiological processes, remarkably they have only formally been recognized for less than fifteen years. These endogenously produced short non-coding RNAs have created a new paradigm of gene control and have utility as both novel biomarkers of cancer and as potential therapeutics. In this review we consider the role of miRNAs in lymphoid biology both under physiological (i.e. lymphopoiesis) and malignant (i.e. lymphomagenesis) conditions. In addition to the functional significance of aberrant miRNA expression in lymphomas we discuss their use as novel biomarkers, both as a in situ tumour biomarker and as a non-invasive surrogate for the tumour by testing miRNAs in the blood of patients. Finally we consider the use of these molecules as potential therapeutic agents for lymphoma (and other cancer) patients and discuss some of the hurdles yet to be overcome in order to translate this potential into clinical practice
Collapse
Affiliation(s)
| | - Lorea Manterola
- Oncology area, Biodonostia Research Institute, San Sebastián, Spain
| | - Charles H Lawrie
- Oncology area, Biodonostia Research Institute, San Sebastián, Spain; ; Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK;; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
43
|
Wong KK, Ch'ng ES, Loo SK, Husin A, Muruzabal MA, Møller MB, Pedersen LM, Pomposo MP, Gaafar A, Banham AH, Green TM, Lawrie CH. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Exp Mol Pathol 2015; 99:537-45. [DOI: 10.1016/j.yexmp.2015.08.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 08/31/2015] [Indexed: 10/23/2022]
|
44
|
Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun 2015; 6:8428. [PMID: 26455434 DOI: 10.1038/ncomms9428] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Accepted: 08/21/2015] [Indexed: 12/12/2022] Open
Abstract
Although transcriptional activation by NF-κB is well appreciated, physiological importance of transcriptional repression by NF-κB in cancer has remained elusive. Here we show that an HDAC4-RelB-p52 complex maintains repressive chromatin around proapoptotic genes Bim and BMF and regulates multiple myeloma (MM) survival and growth. Disruption of RelB-HDAC4 complex by a HDAC4-mimetic polypeptide blocks MM growth. RelB-p52 also represses BMF translation by regulating miR-221 expression. While the NIK-dependent activation of RelB-p52 in MM has been reported, we show that regardless of the activation status of NIK and the oncogenic events that cause plasma cell malignancy, several genetically diverse MM cells including Bortezomib-resistant MM cells are addicted to RelB-p52 for survival. Importantly, RelB is constitutively phosphorylated in MM and ERK1 is a RelB kinase. Phospho-RelB remains largely nuclear and is essential for Bim repression. Thus, ERK1-dependent regulation of nuclear RelB is critical for MM survival and explains the NIK-independent role of RelB in MM.
Collapse
Affiliation(s)
- Subrahmanya D Vallabhapurapu
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Sunil K Noothi
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Derek A Pullum
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Charles H Lawrie
- Department of Oncology, Biodonostia Research Institute, San Sebastián 20014, Spain.,Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford OX3 9DU, UK
| | - Rachel Pallapati
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Veena Potluri
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Christian Kuntzen
- Department of Medicine, Bridgeport Hospital, 267 Grant Street, Bridgeport, Connecticut 06610, USA
| | - Sohaib Khan
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - David R Plas
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| | - Robert Z Orlowski
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
| | - Marta Chesi
- Department of Hematology/Oncology , Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, Arizona 85259, USA
| | - W Michael Kuehl
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Building 37, Room 6002C, Bethesda, Maryland 20892, USA
| | - P Leif Bergsagel
- Department of Hematology/Oncology , Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, Arizona 85259, USA
| | - Michael Karin
- Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California, San Diego, California 92093, USA
| | - Sivakumar Vallabhapurapu
- The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
| |
Collapse
|
45
|
Lawrie CH. Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia. EBioMedicine 2015; 2:489-90. [PMID: 26288811 PMCID: PMC4535125 DOI: 10.1016/j.ebiom.2015.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 05/09/2015] [Indexed: 11/25/2022] Open
Affiliation(s)
- Charles H Lawrie
- Oncology Area, Biodonostia Research Institute, San Sebastián, Spain
| |
Collapse
|
46
|
Sanromán-Iglesias M, Zhang KAI, Chuvilin A, Lawrie CH, Grzelczak M, Liz-Marzán LM. Conjugated Polymers As Molecular Gates for Light-Controlled Release of Gold Nanoparticles. ACS Appl Mater Interfaces 2015; 7:15692-15695. [PMID: 26177362 DOI: 10.1021/acsami.5b05087] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The remote release of nano-objects from a container is a promising approach to transduce chemical events into an optical signal. The major challenge in the development of such a system involves the use of a suitable molecular gate that retains aggregated particles and releases them upon applying an external stimulus. We show proof-of-concept experiments for the release of gold nanoparticles into an aqueous solution upon photodegradation of conjugated polymer thin films. Gold nanoparticles thus transduce light-induced chemical events into an amplified optical signal with a release rate of 2.5 nM per hour, which can be readily detected by the naked eye.
Collapse
Affiliation(s)
- Maria Sanromán-Iglesias
- †CIC biomaGUNE, Paseo de Miramón 182, 20009 Donostia-San Sebastián, Spain
- ‡Oncology Area, Biodonostia Research Institute, Donostia-San Sebastián, Spain
| | - Kai A I Zhang
- §Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany
| | - Andrey Chuvilin
- ⊥CIC nanoGUNE Consolider, Avenida de Tolosa 76, 20018 Donostia-San Sebastián, Spain
- #Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Charles H Lawrie
- ‡Oncology Area, Biodonostia Research Institute, Donostia-San Sebastián, Spain
- #Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Marek Grzelczak
- †CIC biomaGUNE, Paseo de Miramón 182, 20009 Donostia-San Sebastián, Spain
- #Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Luis M Liz-Marzán
- †CIC biomaGUNE, Paseo de Miramón 182, 20009 Donostia-San Sebastián, Spain
- #Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| |
Collapse
|
47
|
Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D, Lawrie CH. The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med 2015; 19:2307-23. [PMID: 26119132 PMCID: PMC4594673 DOI: 10.1111/jcmm.12625] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 05/07/2015] [Indexed: 12/12/2022] Open
Abstract
The gold standard for cancer diagnosis remains the histological examination of affected tissue, obtained either by surgical excision, or radiologically guided biopsy. Such procedures however are expensive, not without risk to the patient, and require consistent evaluation by expert pathologists. Consequently, the search for non-invasive tools for the diagnosis and management of cancer has led to great interest in the field of circulating nucleic acids in plasma and serum. An additional benefit of blood-based testing is the ability to carry out screening and repeat sampling on patients undergoing therapy, or monitoring disease progression allowing for the development of a personalized approach to cancer patient management. Despite having been discovered over 60 years ago, the clear clinical potential of circulating nucleic acids, with the notable exception of prenatal diagnostic testing, has yet to translate into the clinic. The recent discovery of non-coding (nc) RNA (in particular micro(mi)RNAs) in the blood has provided fresh impetuous for the field. In this review, we discuss the potential of the circulating transcriptome (coding and ncRNA), as novel cancer biomarkers, the controversy surrounding their origin and biology, and most importantly the hurdles that remain to be overcome if they are really to become part of future clinical practice.
Collapse
Affiliation(s)
| | - Lorea Manterola
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain
| | - Erika Larrea
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain
| | - Ibai Goicoechea
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain
| | - María Arestin
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain
| | - María Armesto
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain
| | - David Otaegui
- Multiple Sclerosis Group, Biodonostia Research Institute, San Sebastian, Spain
| | - Charles H Lawrie
- Oncology Area, Biodonostia Research Institute, San Sebastian, Spain.,Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
48
|
Lawrie CH, Manterola L, Fernandez-Mercado M, Larrea E, Goicoechea I, Arestin M, Armesto M, Hernandez L. MicroRNAs as B-cell lymphoma biomarkers. Blood Lymphat Cancer 2015. [DOI: 10.2147/blctt.s60481] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
49
|
Wong KK, Gascoyne DM, Brown PJ, Soilleux EJ, Snell C, Chen H, Lyne L, Lawrie CH, Gascoyne RD, Pedersen LM, Møller MB, Pulford K, Murphy D, Green TM, Banham AH. Erratum: Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia 2014. [DOI: 10.1038/leu.2013.276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Lawrie CH, Larrea E, Larrinaga G, Goicoechea I, Arestin M, Fernandez-Mercado M, Hes O, Cáceres F, Manterola L, López JI. Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. J Pathol 2013; 232:32-42. [DOI: 10.1002/path.4296] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2013] [Revised: 09/23/2013] [Accepted: 10/15/2013] [Indexed: 12/15/2022]
Affiliation(s)
- Charles H Lawrie
- Oncology Area; Biodonostia Research Institute; San Sebastian Spain
- Nuffield Department of Clinical Laboratory Sciences; University of Oxford; UK
- IKERBASQUE; Basque Foundation for Science; Bilbao Spain
| | - Erika Larrea
- Oncology Area; Biodonostia Research Institute; San Sebastian Spain
| | - Gorka Larrinaga
- Nursing School; University of the Basque Country (UPV/EHU); Leioa Bizkaia Spain
| | - Ibai Goicoechea
- Oncology Area; Biodonostia Research Institute; San Sebastian Spain
| | - María Arestin
- Oncology Area; Biodonostia Research Institute; San Sebastian Spain
| | | | - Ondrej Hes
- Department of Pathology; Charles University Hospital; Plzen Czech Republic
| | - Francisco Cáceres
- Department of Urology; Cruces University Hospital; Barakaldo Bizkaia Spain
| | - Lorea Manterola
- Oncology Area; Biodonostia Research Institute; San Sebastian Spain
| | - José I López
- Department of Pathology, Cruces University Hospital, BioCruces Research Institute; University of the Basque Country (UPV/EHU); Barakaldo Bizkaia Spain
| |
Collapse
|